Clinical Trials At Southeast Nebraska Cancer Center

HEMATOLOGIC CANCER

CONNECT MDS/AML – The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

informCLL- A Disease Registry for Patients with Chronic Lymphocytic Leukemia

PERSPECTIVE – A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma

PREAMBLE – Prospective Research Assessment in Multiple Myeloma:  An observational Evaluation (PREAMBLE)

UNITY 205 – A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 (Umbralisib) with or without Bendamustine and TGR-1202 (Umbralisib) alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

GASTROINTESTINAL CANCER

CT4006 – A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with  Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

THORACIC CANCER

INTR@PID – A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

COAST – A Phase 2, Open-Label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)

OTHER DIAGNOSES

LYNK-002 – A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

LEAP-004 – A Multicenter, Open-Label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent